New drug combo aims to shrink hard-to-treat stomach cancers
NCT ID NCT07546812
First seen Apr 25, 2026 · Last updated May 09, 2026 · Updated 1 time
Summary
This study tests a new drug called denikitug, alone or with other treatments, in people with advanced HER2-negative stomach, gastroesophageal junction, or esophageal cancer that has spread or come back after initial therapy. About 120 participants will be randomly assigned to receive denikitug by itself or combined with nivolumab or chemotherapy. The main goal is to see if these treatments can shrink tumors.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ESOPHAGEAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.